This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Osteoporosis	Sphingosine-1-phosphate receptor 2 (S1PR2; S1P2; EDG5)	<p>Studies in mice suggest that inhibiting S1PR2 could help treat osteoporosis. In two mouse models of osteoporosis, an S1PR2 antagonist decreased bone density loss compared with vehicle control. Next steps include identifying S1PR2 inhibitors for clinical development.</p> <p>SciBX 4(2); doi:10.1038/scibx.2011.48 Published online Jan. 13, 2011</p>	Patent and licensing status unavailable	<p>Ishii, M. <i>et al. J. Exp. Med.</i>; published online Dec, 6, 2010; doi:10.1084/jem.20101474 Contact: Ronald N. Germain, National Institutes of Health, Bethesda, Md. e-mail: rgermain@niaid.nih.gov Contact: Masaru Ishii, Osaka University, Osaka, Japan e-mail: mishii@ifrec.osaka-u.ac.jp</p>